Merck & Co., Inc. $MRK Shares Purchased by CI Investments Inc.

CI Investments Inc. raised its stake in Merck & Co., Inc. (NYSE:MRK) by 24.5% during the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 1,237,783 shares of the company’s stock after purchasing an additional 243,661 shares during the period. Merck & Co., Inc. accounts for about 0.7% of CI Investments Inc.’s holdings, making the stock its 28th biggest position. CI Investments Inc.’s holdings in Merck & Co., Inc. were worth $148,893,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in MRK. Kingdom Financial Group LLC. purchased a new stake in shares of Merck & Co., Inc. in the 4th quarter valued at about $25,000. Prosperity Bancshares Inc acquired a new stake in shares of Merck & Co., Inc. in the 4th quarter valued at about $26,000. Abound Financial LLC purchased a new position in Merck & Co., Inc. during the 4th quarter worth approximately $26,000. IFC & Insurance Marketing Inc. purchased a new position in Merck & Co., Inc. during the 4th quarter worth approximately $31,000. Finally, High Note Wealth LLC increased its position in Merck & Co., Inc. by 58.9% during the fourth quarter. High Note Wealth LLC now owns 294 shares of the company’s stock worth $31,000 after buying an additional 109 shares during the period. Institutional investors and hedge funds own 76.07% of the company’s stock.

Key Stories Impacting Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Merck and Gilead announced that Phase 3 data from the investigational once-weekly oral HIV regimen combining islatravir and lenacapavir will be presented at AIDS 2026, with the primary endpoint showing maintained viral suppression in adults who switched therapies. The update highlights progress in a potentially important HIV program and could support long-term growth expectations. Article: Investigational Once-Weekly Oral HIV Treatment Regimen of Islatravir and Lenacapavir Maintained Virological Suppression in Adults With HIV Who Switched Antiretroviral Therapy
• Positive Sentiment: Phanes Therapeutics expanded its clinical trial collaboration with Merck to evaluate spevatamig with KEYTRUDA and chemotherapy in first-line biliary tract cancer. More combination-trial activity around KEYTRUDA reinforces Merck’s oncology franchise and keeps the company involved in additional mid- to long-term growth opportunities. Article: Phanes Therapeutics Announces Expansion of Clinical Trial Collaboration and Supply Agreement with Merck to Evaluate Spevatamig in Combination with KEYTRUDA® (Pembrolizumab) and Chemotherapy for Treatment of Biliary Tract Cancer
• Neutral Sentiment: Analyst-focused coverage repeated the view that Wall Street’s bullish average rating suggests Merck is worth considering, but the article also questioned how reliable consensus broker recommendations are as a signal. This is more of a sentiment check than a new fundamental catalyst. Article: Is It Worth Investing in Merck (MRK) Based on Wall Street’s Bullish Views?
• Neutral Sentiment: Recent media commentary also noted that Merck had declined more than the broader market in the prior session and that one rating was lowered to Hold, but these items do not appear to reflect a major company-specific setback. Instead, they suggest some near-term caution after the recent move. Article: Merck (MRK) Declines More Than Market: Some Information for Investors
• Negative Sentiment: Coverage from Barron’s focused on what comes after Keytruda, underscoring investor concern about Merck’s long-term dependence on its flagship cancer drug and the need for a future standard-of-care franchise. That narrative can weigh on valuation if investors worry about the post-Keytruda pipeline. Article: What Comes After Merck’s Keytruda? The Race for the Next Standard Cancer Treatment.

Merck & Co., Inc. Stock Performance

Shares of MRK stock opened at $126.27 on Wednesday. The stock’s 50-day moving average price is $120.65 and its 200 day moving average price is $117.29. The company has a quick ratio of 1.06, a current ratio of 1.30 and a debt-to-equity ratio of 1.02. The stock has a market capitalization of $311.86 billion, a PE ratio of 35.57, a price-to-earnings-growth ratio of 4.95 and a beta of 0.19. Merck & Co., Inc. has a 52-week low of $76.66 and a 52-week high of $131.74.

Merck & Co., Inc. (NYSE:MRK) last posted its quarterly earnings data on Thursday, April 30th. The company reported ($1.28) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.47) by $0.19. Merck & Co., Inc. had a return on equity of 27.55% and a net margin of 13.59%.The company had revenue of $16.29 billion during the quarter, compared to analysts’ expectations of $15.85 billion. During the same period last year, the firm earned $2.22 EPS. The firm’s revenue for the quarter was up 4.9% on a year-over-year basis. Merck & Co., Inc. has set its FY 2026 guidance at 5.040-5.160 EPS. As a group, equities research analysts forecast that Merck & Co., Inc. will post 2.74 EPS for the current year.

Merck & Co., Inc. Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Wednesday, July 8th. Stockholders of record on Monday, June 15th were paid a dividend of $0.85 per share. This represents a $3.40 annualized dividend and a dividend yield of 2.7%. The ex-dividend date was Monday, June 15th. Merck & Co., Inc.’s dividend payout ratio is 95.77%.

Wall Street Analysts Forecast Growth

MRK has been the subject of a number of research reports. Guggenheim boosted their price objective on Merck & Co., Inc. from $140.00 to $145.00 and gave the company a “buy” rating in a research note on Monday, July 13th. CICC Research began coverage on shares of Merck & Co., Inc. in a research report on Wednesday, June 24th. They set an “outperform” rating and a $138.00 target price on the stock. UBS Group lifted their target price on shares of Merck & Co., Inc. from $130.00 to $145.00 and gave the company a “buy” rating in a report on Monday, April 13th. Scotiabank upped their price target on shares of Merck & Co., Inc. from $136.00 to $155.00 and gave the company a “sector outperform” rating in a research report on Tuesday, June 30th. Finally, Bank of America increased their price target on shares of Merck & Co., Inc. from $130.00 to $141.00 and gave the stock a “buy” rating in a research note on Tuesday, June 30th. One research analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating and seven have given a Hold rating to the company’s stock. According to MarketBeat, Merck & Co., Inc. presently has a consensus rating of “Moderate Buy” and a consensus price target of $133.94.

About Merck & Co., Inc.

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.